Tg Therapeutics (TGTX) Amortization of Deferred Charges (2011 - 2026)

Tg Therapeutics' Amortization of Deferred Charges history runs 10 years deep, the most recent figure standing at $285000.0 for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 6.25% year-over-year to $285000.0 in Q1 2026; TTM through Mar 2026 was $1.7 million, a 63.81% decrease from a year earlier, with the FY2025 full-year figure at $1.7 million, down 8.0% from the prior year.
• Amortization of Deferred Charges slipped to $285000.0 in Q1 2026 per TGTX's latest filing, from $432000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $4.0 million in Q3 2024 and bottomed at $208000.0 in Q4 2024.
• The 5-year median for Amortization of Deferred Charges is $500000.0 (2022), against an average of $737882.4.
• Across the five-year window, Amortization of Deferred Charges jumped 566.67% in 2024 and sank 89.22% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $1.3 million in 2022, then slumped by 32.06% to $905000.0 in 2023, then slumped by 77.02% to $208000.0 in 2024, then surged by 107.69% to $432000.0 in 2025, then plunged by 34.03% to $285000.0 in 2026.
• Per Business Quant, the three latest TGTX Amortization of Deferred Charges figures stand at $285000.0 (Q1 2026), $432000.0 (Q4 2025), and $431000.0 (Q3 2025).